The FDA said it has received reports of clogging problems with
the drug although no problems were reported with patients who took
the product by mouth. Teva has voluntarily withdrawn its version of
the drug from distribution but the FDA cautioned on its website
that some stock may remain in pharmacies, other facilities or in
patients' possession. The drug is a generic version of Takeda's
Prevacid.

The orally disintegrating tablet version is designed to
disintegrate when water is added to them. However, according to
reports, the Teva tablets may not fully disintegrate, or may later
form clumps that can stick to the inside walls of oral syringes and
feeding tubes. In some cases, patients have had to seek emergency
medical assistance and their feeding tubes had to be unclogged, or
removed and replaced, the FDA said. The FDA said it will continue
to review and monitor the issue and is seeking prompt correction of
the problem by Teva.

Teva's share price was down 0.5 percent to NIS 169.50 on the
TASE this morning. The share price rose 0.2 percent to $50.01 on
Nasdaq on Friday, giving a market cap of $44.91 billion.

To see more of the Globes or to subscribe to the newspaper, go
to http://www.globes-online.com.